Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human phase 1 study of AMG232 in advanced solid tumors or multiple myeloma
NL-OMON44939Phase 1Active, not recruiting
- Sponsor
- Amgen
- Start
- Jun 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of navtemadlin in Nonhematologic neoplasms and multiple myeloma (MM) (4 arms), sponsored by Amgen. Started Jun 2013; status: active, not recruiting.
02
Drugs
navtemadlin
03
Conditions
Nonhematologic neoplasmsmultiple myeloma (MM)
Beyond the preview
Go deeper on NL-OMON44939.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44939.